Abstract 2608: The super enhancer-driven long noncoding RNA lncNB promotes neuroblastoma tumorigenesis by interacting with MSI2 protein and is targetable by small molecule compounds

Abstract Background: While MYCN-amplified neuroblastoma has been the focus of neuroblastoma research in the past three decades, most human neuroblastomas do not harbour MYCN oncogene amplification, and their tumorigenic factors are unknown. Long non-coding RNAs (lncRNAs) regulate tumorigenesis by modulating the expression of molecular targets, however, there is limited literature on therapeutic targeting of lncRNAs with small molecule compounds. Aims: To determine the oncogenic mechanism though which the lncRNA lncNB promotes neuroblastoma cell proliferation, survival and tumour progression; and to identify a small molecule compound that inhibits the interaction between lncNB and its binding protein MSI2 as an effective anticancer strategy. Methods and results: Kaplan Meier analysis showed that high levels of lncNB expression in neuroblastoma tissues correlated with poor prognosis in 476 patients. We identified lncNB as the lncRNA most over-expressed in MYCN non-amplified, compared with MYCN-amplified, neuroblastoma cell lines. lncNB expression was controlled by super-enhancers, and lncNB RNA bound to MSI2 protein. RNA immunoprecipitation and sequencing identified BMX mRNA as the transcript most significantly disrupted from binding to MSI2 protein, after lncNB knockdown. lncNB or MSI2 knockdown reduced, while their over-expression enhanced, BMX mRNA stability and expression, ERK protein phosphorylation and MYCN non-amplified neuroblastoma cell proliferation. lncNB knockdown significantly suppressed neuroblastoma progression in mice. AlphaScreen of a compound library identified NSC617570 as an efficient inhibitor of lncNB RNA and MSI2 protein interaction, and NSC617570 reduced BMX expression, ERK protein phosphorylation, neuroblastoma cell proliferation in vitro and tumor progression in mice. Conclusions: Our study demonstrates that lncNB RNA interacts with MSI2 protein to induce neuroblastoma tumorigenesis, and that targeting lncNB and MSI2 interaction with small molecule compounds is an effective anticancer strategy. Citation Format: Sujanna Mondal, Pei Y. Liu, Janith Seneviratne, Antoine De Weck, Pooja Venkat, Chelsea Mayoh, Jing Wu, Jesper Maag, Jingwei Chen, Matthew Wong, Nenad Bartonicek, Poh Khoo, Lei Jin, Louise E. Ludlow, David S. Ziegler, Toby Trahair, Pieter Mestdagh, Belamy B. Cheung, Jinyan Li, Marcel E. Dinger, Ian Street, Xu D. Zhang, Glenn M. Marshall, Tao Liu. The super enhancer-driven long noncoding RNA lncNB promotes neuroblastoma tumorigenesis by interacting with MSI2 protein and is targetable by small molecule compounds [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2608.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2025-04-21
DOI
https://doi.org/10.1158/1538-7445.am2025-2608
Primary Topic
Cancer-related molecular mechanisms research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 2608: The super enhancer-driven long noncoding RNA lncNB promotes neuroblastoma tumorigenesis by interacting with MSI2 protein and is targetable by small molecule compounds

Belamy B. Cheung, Jinyan Li, Jesper L.V. Mååg, Toby N. Trahair et al.
Cancer Research
Cancer-related molecular mechanisms research
article

Abstract 2608: The super enhancer-driven long noncoding RNA lncNB promotes neuroblastoma tumorigenesis by interacting with MSI2 protein and is targetable by small molecule compounds

Belamy B. Cheung, Jinyan Li, Jesper L.V. Mååg, Toby N. Trahair, Louise Ludlow, Ian P. Street, Matthew Wai Kin Wong, Sujanna Mondal, Tao Liu, Nenad Bartoniček, David S. Ziegler, Pei Y. Liu, Marcel E. Dinger, Chelsea Mayoh, Pieter Mestdagh, Janith A. Seneviratne, Jingwei Chen, Pooja Venkat, Lei Jin, Xu Dong Zhang, Antoine de Weck, Jing Wu, G M Marshall, Poh Sim Khoo
article en

Abstract

Abstract Background: While MYCN-amplified neuroblastoma has been the focus of neuroblastoma research in the past three decades, most human neuroblastomas do not harbour MYCN oncogene amplification, and their tumorigenic factors are unknown. Long non-coding RNAs (lncRNAs) regulate tumorigenesis by modulating the expression of molecular targets, however, there is limited literature on therapeutic targeting of lncRNAs with small molecule compounds. Aims: To determine the oncogenic mechanism though which the lncRNA lncNB promotes neuroblastoma cell proliferation, survival and tumour progression; and to identify a small molecule compound that inhibits the interaction between lncNB and its binding protein MSI2 as an effective anticancer strategy. Methods and results: Kaplan Meier analysis showed that high levels of lncNB expression in neuroblastoma tissues correlated with poor prognosis in 476 patients. We identified lncNB as the lncRNA most over-expressed in MYCN non-amplified, compared with MYCN-amplified, neuroblastoma cell lines. lncNB expression was controlled by super-enhancers, and lncNB RNA bound to MSI2 protein. RNA immunoprecipitation and sequencing identified BMX mRNA as the transcript most significantly disrupted from binding to MSI2 protein, after lncNB knockdown. lncNB or MSI2 knockdown reduced, while their over-expression enhanced, BMX mRNA stability and expression, ERK protein phosphorylation and MYCN non-amplified neuroblastoma cell proliferation. lncNB knockdown significantly suppressed neuroblastoma progression in mice. AlphaScreen of a compound library identified NSC617570 as an efficient inhibitor of lncNB RNA and MSI2 protein interaction, and NSC617570 reduced BMX expression, ERK protein phosphorylation, neuroblastoma cell proliferation in vitro and tumor progression in mice. Conclusions: Our study demonstrates that lncNB RNA interacts with MSI2 protein to induce neuroblastoma tumorigenesis, and that targeting lncNB and MSI2 interaction with small molecule compounds is an effective anticancer strategy. Citation Format: Sujanna Mondal, Pei Y. Liu, Janith Seneviratne, Antoine De Weck, Pooja Venkat, Chelsea Mayoh, Jing Wu, Jesper Maag, Jingwei Chen, Matthew Wong, Nenad Bartonicek, Poh Khoo, Lei Jin, Louise E. Ludlow, David S. Ziegler, Toby Trahair, Pieter Mestdagh, Belamy B. Cheung, Jinyan Li, Marcel E. Dinger, Ian Street, Xu D. Zhang, Glenn M. Marshall, Tao Liu. The super enhancer-driven long noncoding RNA lncNB promotes neuroblastoma tumorigenesis by interacting with MSI2 protein and is targetable by small molecule compounds [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2608.

Cancer ResearchVol. 85(8_Supplement_1)
Garvan Institute of Medical Research (AU), Ghent University Hospital (BE), Cancer Australia (AU), Children's Cancer Institute Australia (AU), Shenzhen Institutes of Advanced Technology (CN), Murdoch Children's Research Institute (AU), University of Newcastle Australia (AU)
Openalex Percentile: Top 91%
Cancer-related molecular mechanisms research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.